



The Global State of HCT for Non-Malignant Diseases (NMD): Results of the WBMT Survey

Dietger Niederwieser
University Leipzig, Germany


WBMT Activities

- Promote development of new HCT facilities, especially in countries with limited resources.
- Organize workshops in interested countries.
- Provide mentoring/educational options on individual basis.
- Promote quality and safety in all areas of HCT, stem cell donation and donor follow-up.
- Assist HCT programs in worldwide challenges.

Figure 1




WBMT: maximum overall number
of reporting teams per country:
1 848




Worldwide Network for Blood and Marrow Transplantation
NGO in official relations with World Health Organization

Global Transplant Activity reporting sheet





Country/Hospital:		WBMT Global Transplant Activity (GTA) Year =																	
Contact E mail: No. Teams reporting: No. Teams known to transplant but do not report:		PLEASE REPORT THE NUMBER OF PATIENTS RECEIVING THEIR FIRST TRANSPLANT ONLY FOR THE SURVEY YEAR																	
		NUMBER OF PATIENTS RECEIVING FIRST TRANSPLANTS ONLY																	
		Allogeneic												Autologous			Total		
		HLA - id sibling			Family member donor			Unrelated donor											
		BM	PBSC	Cord	BM	PBSC	Cord	BM	PBSC	Cord	BM	PBSC	Cord	BM	PBSC	Cord	ALLO	AUTO	TOTAL
LEUKEMIAS	Indication																		
	AML, 1st CR																		
	AML, non 1st CR																		
	ALL, 1st CR																		
	ALL, non 1st CR																		
	CML, 1st cP																		
	CML, not 1st cP																		
	Other Leukemias																		
	MDS or MD/MPN																		
	MPN																		
LYMPHOPLASMACTIC DISORDERS	CLL incl. PLL																		
	PCD - Myeloma																		
	PCD - other																		
	HD																		
	NHL																		
SOLID TUMORS	Other LPD																		
	Neuroblastoma																		
	Germ cell tumor																		
	Breast Cancer																		
	Ewing																		
NON MALIGNANT DISORDERS	Other solid tumor																		
	BMF - SAA																		
	BMF - other																		
	Hemoglobinopathy																		
	Primary Immune Deficiency																		
	Inherited Dis of Metabolism																		
	Auto Immune Disease																		
Other Non Malignant Disease																			
Other (incl Histiocytosis)																			
TOTAL PATIENTS (1st HSCT)																			
TOTAL NUMBER OF TRANSPLANTS PERFORMED THIS YEAR: includes 1st, 2nd, 3rd, etc.		ALLO:			AUTO:			TOTAL:											
EBMT CIC No. / CIBMTR Code / APBMT (if member):																			



Please return to Helen Baldomero; Fax: 00 41 61 255 2735, E-mail: Helen.Baldomero@usb.ch, post: Helen Baldomero, Hematology, University Hospital Basel, CH-4031 Basel, Switzerland.

*Worldwide Network for Blood and Marrow Transplantation
NGO in official relations with World Health Organization*


WBMt global survey: Trend 2006-2018 (prelim) type and source




WBMT global survey: HSCT by region 2006-2018 (*prelim*)



Allogeneic HSCT



Autologous HSCT



WBMT global survey: 2018

GLOBAL data 2018

Teams = 1768 preliminary data

	Allogeneic			Autologous	Total
	Family	Unrelated	Total		
Leukemia's	18219	14847	33066	841	33907
AML	8985	7232	16217	622	16839
ALL	5110	3104	8214	165	8379
CML	565	443	1008	1	1009
MDS/MPS	3188	3734	6922	6	6928
CLL	151	211	362	27	389
Other leukemia	220	123	343	20	363
Lymphoproliferative disorders	2072	1666	3738	43914	47652
PCD	265	300	565	26746	27311
HD/NHL	1735	1486	3221	16462	19683
Other lymphoma/Type unknown	72	24	96	706	802
Solid tumors	65	42	107	2979	3086
Non malignant disorders	4540	2263	6803	880	7683
Bone marrow failures	2288	918	3206	7	3213
Hemoglobinopathies	1374	442	1816	17	1833
Immune deficiencies	631	575	1206	21	1227
Inherited diseases of metabolism	137	217	354	39	393
Autoimmune disorders	22	17	39	791	830
Other Non malignant disorders	88	94	182	5	187
Others	156	118	274	66	340
TOTAL	25052	19080	44132	48680	92812


2006	2016	Δ%	2016
		(06-16)	%
Total			
16118	29563	83,4	35.7
7880	14965	89,9	18.1
3697	7050	90,7	8.5
1348	1109	-17,7	1.3
2327	5626	141,8	6.8
729	482	-33,9	0.6
137	331	141.6	0.4
24874	43850	76,3	53.0
11448	24361	112,8	29.5
13426	19349	44,1	23.4
0	140		0.2
2710	2937	8,4	3.6
2553	6118	139,6	7.3
1292	2690	108,2	3.3
395	1273	222,3	1.5
448	987	120,3	1.2
			0.4
179	297	65,9	
200	678	239,0	0.8
			0.2
39	193	394,9	
308	250	-18.8	0.3
46563	82718	77.6	100

WBMT global survey: Main diagnosis 2018 (prelim)




HSCT


allogeneic



autologous



HCT increase/decrease (Δ) by disease and region from 2006 to 2016






Figure 5. Projections of estimated newborns with SCA between 2010 and 2050. Projections of estimated number of newborns with SCA (y-axis) between 2010 and 2050 for the DRC, India, and Nigeria (in blue); HbS regions: Eurasia, the Americas, sub-Saharan Africa, Southeast Asia, and Arab-India (in red; defined in Piel et al. [21]); and globally (in green). The dark-shaded areas represent the uncertainty in the demographic data. The light-shaded areas show the uncertainty associated with our estimates of SCA frequency.

doi:10.1371/journal.pmed.1001484.g005